Recent developments in tuberculosis vaccines

Current Opinion in Infectious Diseases

Volumn 18, Issue 3, 2005, Pages 211-215

  Haile, Melles ^a,b   Källenius, Gunilla ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

BCG; Booster vaccination; Tuberculosis vaccine

Indexed keywords

ADJUVANT; BCG VACCINE; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; EUROCINE; HEAT SHOCK PROTEIN 60; HYBRID PROTEIN; NEW DRUG; PROTEIN AG85B; PROTEIN MTB; PROTEIN MTB32; PROTEIN MTB39; RECOMBINANT BCG VACCINE 30; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMERICAN INDIAN; BACTERIAL STRAIN; BCG VACCINATION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENVIRONMENTAL FACTOR; FOLLOW UP; HEALTH PROGRAM; HUMAN; IMMUNITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 20044361834     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000168380.08895.9a     Document Type: Review

References (53)

1. Fine PE, Carneiro AMI, Milstien BJ. Issues relating to the use of BCG in immunization programmes: a discussion document. WHO Bull 1999; 23.
2. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994; 271:698-702.
3. Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 2004; 291:2086-2091. The authors study the long-term efficacy of BCG. Women were significantly better protected than men. There are some important differences in the vaccine preparation procedures compared with a previous large-scale study in South India, where no protection was seen with the same vaccine. In this study the vaccine used was prepared freshly on site and not in a lyophilized form as in the study in South India. This correlates with the good efficacy seen in a MRC trial in the 1950s, which showed high efficacy with liquid vaccines.
4. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339-1345.
5. Hart PD. Efficacy and applicability of mass BCG vaccination in tuberculosis control. BMJ 1967; 1:587-592.
6. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by wholegenome DNA microarray. Science 1999; 284:1520-1523.
7. Vordermeier HM, Cockle PC, Whelan A, et al. Development of diagnostic reagents to differentiate between Mycobacterium bovis BCG vaccination and M. bovis infection in cattle. Clin Diagn Lab Immunol 1999; 6:675-682.
8. Baily GV. Tuberculosis prevention trial, Madras. Indian J Med Res 1980; 72(Suppl):1-74.
9. Orme IM, Collins FM. Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Infect Immun 1984; 44:28-32.
10. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966; 94:553-568.
11. Fine PE. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989; 11(Suppl 2):S353-S359.
12. Rook GA, Bahr GM, Stanford JL. The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG. Tubercle 1981; 62:63-68.
13. Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70:672-678.
14. Buddle BM, Wards BJ, Aldwell FE, et al. Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine 2002; 20:1126-1133.
15. de Lisle GW, Wards BJ, Buddle BM, Collins DM. The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium. Tuberculosis (Edinb) 2005; 85:73-79. In this study the authors evaluated the protective efficacy of live attenuated M. bovis strains as a vaccine after presensitization with environmental mycobacteria (M. avium containing or not the IS901 DNA insertion) in guinea pigs. Different inoculation routes of the vaccine, as well as the level of protective efficacy, are evaluated.
16. Malhotra I, Mungai P, Wamachi A, et al. Helminth- and Bacillus Calmette-Guérin induced immunity in children sensitized in utero to filariasis and schistosomiasis. J Immunol 1999; 162:6843-6848.
17. Elias D, Akuffo H, Pawlowski A, et al. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine 2005; 23:1326-1334. In animal models of TB infection, prevaccination exposure of mice to chronic helminth infection reduces the protective efficacy of the ensuing BCG. The immune response is polarized towards a Th2 type.
18. Elias D, Wolday D, Akuffo H, et al. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guérin (BCG) vaccination. Clin Exp Immunol 2001; 123:219-225.
19. Haile M, Schroder U, Hamasur B, et al. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guérin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine 2004; 22:1498-1508. Vaccination of mice with a heat-killed BCG formulated in L3 adjuvant followed by booster with the same formulation by the intranasal route was found as protective as vaccination with live BCG in terms of prolonged long-term survival. Several formulations of the heat-killed BCG in L3 adjuvant were compared and their long-term efficacy and immunological responses were analysed and discussed.
20. Aldwell FE, Keen DL, Parlane NA, et al. Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums. Vaccine 2003; 22:70-76.
21. Goonetilleke NP, McShane H, Hannan CM, et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003; 171:1602-1609.
22. Lyadova IV, Vordermeier HM, Eruslanov EB, et al. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFNgamma in their lungs. Clin Exp Immunol 2001; 126:274-279.
23. Doherty TM, Olsen AW, van Pinxteren L, Andersen P. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect Immun 2002; 70:3111-3121.
24. de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev 2003; 1:CD001166.
25. Pinto R, Saunders BM, Camacho LR, et al. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guérin vaccine. J Infect Dis 2004; 189:105-112. A mutant strain of M. tuberculosis, which is defective in translocating the capsular lipid phthiocerol dimycocerosate (DIM), was constructed using signature-tagged mutagenesis, and used as a vaccine. Improved and sustainable protection was seen when compared with BCG.
26. Smith DA, Parish T, Stoker NG, Bancroft GJ. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 2001; 69:1142-1150.
27. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 2000; 97:13853-13858.
28. Pym AS, Brodin P, Majlessi L, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003; 9:533-539.
29. Hess J, Kaufmann SH. Live antigen carriers as tools for improved anti-tuberculosis vaccines. FEMS Immunol Med Microbiol 1999; 23:165-173.
30. Moreira AL, Tsenova L, Murray PJ, et al. Aerosol infection of mice with recombinant BCG secreting murine IFN-gamma partially reconstitutes local protective immunity. Microb Pathog 2000; 29:175-185.
31. Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of anti-mycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc Natl Acad Sci U S A 1996; 93:934-939.
32. McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69:681-686.
33. Mollenkopf HJ, Groine-Triebkorn D, Andersen P, et al. Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA. Vaccine 2001; 19:4028-4035.
34. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-1244. This is the first report on the results of the clinical evaluation of a new TB vaccine candidate. A subunit candidate vaccine, based on heterologous BCG/MVA85A vaccination, is shown to be safe and immunogenic. Preexisting antimycobacterial immune responses (induced either by environmental mycobacteria or BCG vaccination) are enhanced by this new vaccine.
35. Huygen K. DNA vaccines: application to tuberculosis. Int J Tuberc Lung Dis 1998; 2:971-978.
36. Lowrie DB, Silva CL. Enhancement of immunocompetence in tuberculosis by DNA vaccination. Vaccine 2000; 18:1712-1716.
37. Ferraz JC, Stavropoulos E, Yang M, et al. A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infect Immun 2004; 72:6945-6950. Previous studies by the same authors using Hsp65 and Hsp70 as DNA vaccines have shown good protection against TB. In this study using the Mtb Apa (alanine-proline-rich antigen) and mycobacterial Hsp65 and Hsp70 antigens as DNA vaccine, followed by BCG vaccination, significant improvement in the protective efficacy was seen.
38. Lowrie DB. DNA vaccination: an update. Methods Mol Med 2003; 87:377-390.
39. Johansen P, Raynaud C, Yang M, et al. Anti-mycobacterial immunity induced by a single injection of M. leprae Hsp65-encoding plasmid DNA in biodegradable microparticles. Immunol Lett 2003; 90:81-85.
40. Skeiky YA, Alderson MR, Ovendale PJ, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004; 172:7618-7628. Using serological and T cell expression cloning methods, several antigens were identified that stimulate CD4 and CD8 responses in cells derived from PPD+ donors and in mice infected with Mtb. The relevant antigens were then used to construct recombinant fusion protein or naked DNA vaccine, in combination with two adjuvant formulations, and tested in mice and guinea pigs.
41. Evans JT, Ward JR, Kern J, Johnson ME. A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4. Vaccine 2004; 22:1964-1972. This paper highlights how a nonimmunogenic protein antigen when formulated in a microsphere-based vaccine could induce both humoral and T cell immune responses. Several adjuvant formulations were developed and evaluated. The benefits of using a microsphere formulation over other types of delivery systems are also discussed. Different routes of administration were compared to test if vaccination with this new vaccine candidate could stimulate CD8 immune response against TB.
42. Weiss DW. Vaccination against tuberculosis with nonliving vaccines. I: The problem and its historical background. Am Rev Respir Dis 1959; 80:676-688.
43. Haile M, Hamasur B, Jaxmar T, et al. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis (Edinb) 2005; 85:107-114. Using the mouse model two new vaccine candidates which have shown good protection in a prophylactic mode of vaccination are tested for their efficacy as a booster vaccine given intranasally in mice vaccinated with BCG at a young age.
44. Chambers MA, Wright DC, Brisker J, et al. A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome) protects guinea pigs from lethal tuberculosis. Vaccine 2004; 22:1063-1071. The killed, whole cell BCG, formulated together with a liposome adjuvant, was tested for its protective efficacy in guinea pig model. A single dose of the adjuvanted formalin-kilied BCG vaccine was shown to be protective in terms of reduced bacterial loads in lungs and spleens and the increased long-term survival.
45. Vordermeier HM, Rhodes SG, Dean G, et al. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin. Immunology 2004; 112:461-470. The main aim of this paper was to evaluate the cellular immune responses, in particular in-vitro IFN-γ responses in cattle vaccinated with recombinant MVA85A or FP85A in conjunction with BCG. The same vaccine has already gone through phase I clinical evaluation, and is being prepared for large-scale studies in endemic countries (Ref. [18]).
46. McShane H, Pathan AA, Sander CR, et al. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005; 85:47-52. The authors of this paper give a review on preclinical data from a BCG prime-recombinant MVA85A boost vaccine in the UK and Africa. Additionally, ethical and regulatory issues, different aims of TB vaccines, immune correlates of protection, as well as the Koch reaction, are discussed.
47. Lagranderie M, Chavarot P, Balazuc AM, Marchai G. Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice. Vaccine 2000; 18:1186-1195.
48. Lagranderie M, Nahori MA, Balazuc AM, et al. Dendritic cells recruited to the lung shortly after intranasal delivery of Mycobacterium bovis BCG drive the primary immune response towards a type 1 cytokine production. Immunology 2003; 108:352-364.
49. Falero-Diaza G, Challacombea S, Banerjeeb D, et al. Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 2000; 18:3223-3229.
50. Hamasur B, Haile M, Pawlowski A, et al. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine 2003; 21:4081-4093.
51. Wang J, Thorson L, Stokes RW, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004; 173:6357-6365. In this paper, the recombinant replication-deficient, adenoviral vector expressing Mtb Ag85A (AdAgSSA) was tested as mucosal vaccine against TB. Single mucosal vaccination activated both CD4 and CD8 T cells, and enhanced protection more than cutaneous vaccination with BCG.
52. Rowland SS, Mayner RL, Barker L. Advancing TB vaccines to phase I clinical trials in the US: regulatory/manufacturing/licensing issues. Tuberculosis (Edinb) 2005; 85:39-46.
53. Izzo A, Brandt L, Lasco T, et al. NIH pre-clinical screening program: overview and current status. Tuberculosis (Edinb) 2005; 85:25-28.